Get the Stockscreener App
1.58
2.60%
0.04
Humacyte Inc stock is traded at $1.58, with a volume of 3.56M.
It is up +2.60% in the last 24 hours and down -31.30% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.54
Open:
$1.54
24h Volume:
3.56M
Relative Volume:
0.79
Market Cap:
$250.23M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-1.4766
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
-15.96%
1M Performance:
-31.30%
6M Performance:
-55.37%
1Y Performance:
-75.31%
1-Day Range:
$1.50
$1.61
1-Week Range:
$1.47
$1.9399
52-Week Range:
$1.15
$7.48
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.58 | 285.07M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views? - Yahoo Finance
Humacyte Reports Q2 2025 Earnings and Market Expansion - MSN
HUMA Stock Plunge: Buying Opportunity? - StocksToTrade
Humacyte Requests to Dismiss Class Action Filed by Investors - TradingView
Will Humacyte Inc. stock hit new highs in YEARNew Guidance & Daily Profit Focused Screening - thegnnews.com
Investors Hope for Bounce in Humacyte Inc. Equity Warrant After SelloffQuarterly Profit Review & Weekly Watchlist for Hot Stocks - metal.it
Humacyte Inc. Hits Oversold Level on RSI IndicatorAI Driven Entry Signal Forecast - beatles.ru
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. LawsuitHUMA - ACCESS Newswire
Humacyte Inc. Equity Warrant’s volatility index tracking explainedJuly 2025 Review & Technical Pattern Recognition Alerts - Newser
Risk adjusted return profile for Humacyte Inc. analyzedWeekly Stock Recap & Target Return Focused Picks - Newser
Detecting price anomalies in Humacyte Inc. Equity Warrant with AIJuly 2025 Setups & High Accuracy Investment Signals - Newser
Heatmap analysis for Humacyte Inc. and competitorsJuly 2025 Reactions & Consistent Profit Trade Alerts - Newser
How to track smart money flows in Humacyte Inc.July 2025 Breakouts & Expert Verified Stock Movement Alerts - Newser
What technical models suggest about Humacyte Inc. Equity Warrant’s comeback2025 Market Outlook & Daily Profit Maximizing Trade Tips - Newser
Humacyte Inc. stock volume spike explainedJuly 2025 Review & Weekly Stock Performance Updates - Newser
Can machine learning forecast Humacyte Inc. recoveryPortfolio Return Summary & Daily Profit Focused Screening - Newser
Technical Models Suggest Humacyte Inc. Equity Warrant May Rebound SoonJuly 2025 Spike Watch & Long-Term Capital Growth Strategies - sundaytimes.kr
Humacyte Inc. Equity Warrant Could See a Relief Rally From SupportWeekly Loss Report & AI Forecast for Swing Trade Picks - beatles.ru
How to escape a deep drawdown in Humacyte Inc.Weekly Investment Report & Verified Stock Trade Ideas - Newser
How to build a custom watchlist for Humacyte Inc. Equity WarrantRate Hike & AI Enhanced Trading Alerts - Newser
Will Humacyte Inc. outperform the marketTreasury Yields & Technical Analysis for Trade Confirmation - Newser
Is Humacyte Inc. Equity Warrant stock poised for growth2025 Earnings Impact & Weekly High Potential Stock Alerts - Newser
Is Humacyte Inc. a turnaround storyQuarterly Portfolio Report & Fast Exit and Entry Trade Guides - mustnews.co.kr
Real time breakdown of Humacyte Inc. stock performance2025 Bull vs Bear & Verified Entry Point Signals - Newser
News impact scoring models applied to Humacyte Inc.Portfolio Value Summary & High Yield Stock Recommendations - Newser
Exit strategy if you’re trapped in Humacyte Inc. Equity Warrant2025 Support & Resistance & Risk Controlled Swing Alerts - Newser
MACD Cross Could Confirm Trend in Humacyte Inc.2025 Technical Patterns & Verified Short-Term Trading Plans - newsyoung.net
Will a bounce in Humacyte Inc. Equity Warrant offer an exit2025 Year in Review & Reliable Volume Spike Trade Alerts - Newser
Will Humacyte Inc. outperform during market ralliesQuarterly Portfolio Summary & Fast Gaining Stock Reports - classian.co.kr
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors - MSN
Earnings call transcript: Humacyte Q2 2025 misses EPS and revenue targets - Investing.com Australia
Trading Bots Trigger Alerts on Humacyte Inc. ActivityJuly 2025 Recap & Free High Return Stock Watch Alerts - metal.it
Humacyte’s Earnings Call: Progress Amid Challenges - TipRanks
A Quick Look at Today's Ratings for Humacyte(HUMA.US), With a Forecast Between $3 to $14 - 富途牛牛
Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress (NASDAQ:HUMA) - Seeking Alpha
Humacyte stock price target lowered to $3.50 at TD Cowen on mixed outlook - Investing.com Canada
Humacyte stock rating reiterated at Buy by Benchmark despite revenue miss - Investing.com Canada
Humacyte, Inc. (NASDAQ:HUMA) Q2 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright lowers Humacyte stock price target to $3 on weak sales - Investing.com Canada
Analysts Expect Breakeven For Humacyte, Inc. (NASDAQ:HUMA) Before Long - simplywall.st
Humacyte targets over 200 hospital access points for Symvess as VAC approvals surge and cost cuts extend cash runway - MSN
Humacyte Inc (HUMA) Q2 2025 Earnings Call Highlights: Navigating Challenges and Celebrating ... By GuruFocus - Investing.com Canada
Humacyte Inc Navigates Challenges, Celebrates Milestones in Q2 2025 Earnings Call Highlights - AInvest
Humacyte Reports Q2 Revenue Miss, Symvess Shows Progress in Hospital Access and Sales - AInvest
Humacyte Missed Revenue Forecasts But Expanded Symvess Access - Finimize
Humacyte Posts Q2 Revenue Miss - AOL.com
Humacyte: D. Boral Capital Maintains Buy, PT Raised to $25 from $20. - AInvest
Humacyte, Inc. shares fall 31.49% intraday after reporting Q2 revenue of $301,000, far below analyst expectations of $1 million. - AInvest
Humacyte stock price target lowered to $7 at BTIG on mixed Q2 results - Investing.com Canada
Humacyte's 2025 Q2 Earnings Call: Unpacking Key Contradictions on Sales, CMS Impact, and FDA Interactions - AInvest
Sitryx gets back rights to drug from Lilly deal; Humacyte is cutting costs - Endpoints News
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):